Global Automated Microbiology Market, 2021-2025--Growth Opportunities in the US, Europe, Japan--Supplier Shares by Assay, Segmentation Forecasts for over 100 Molecular, Identification, Susceptibility, Culture, Urine Screening and Immunodiagnostic Tests--Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market, 2021-2025 Barriers and Risks

LeadingMarketResearch.com's new report is a seven-country strategic analysis of the major business opportunities emerging in the automated microbiology market during the next five years.

The report is available by section, and can be customized to specific information needs and budget. The report examines key trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, and country; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.

The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratories still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.

This comprehensive seven-country report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies.

Worldwide Market Overview

- Estimated universe of laboratories performing microbiology testing by country.

- Specimen, test volume and sales forecasts by country.

Geographic Coverage

France, Germany, Italy, Japan, Spain, UK, USA

Market Segmentation Analysis

- Sales and market shares for major suppliers by individual test and country.

- Volume and sales forecasts for over 100 infectious disease assays by individual test and country:

- Test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy).

- Review of the market dynamics, trends, structure, size, growth and major suppliers by country.

Specimen Types

- Urine
- Sterile Fluids: Blood, Serum, CSF
- Throat Swabs, Respiratory Secretions
- Genital Secretions
- Stool
- Abscess/Wound
- Sputum
- Saliva

Applications

-Microbial Identification
-Antibiotic Susceptibility
-Urine Screening
-Blood Cultures

Review of Major Automated Systems

- Review of major automated molecular diagnostic, multipurpose, specialized, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic analyzers marketed by Abbott, Halifax, BD, Beckman Coulter/Danaher, Biolog, bioMerieux, Bio-Rad, Cepheid, Curetis, GenMark, Hologic, HTG, Labsystems, Qiagen, Roche, Siemens Healthineers, Sy-Lab, Sysmex, Tecan, Thermo Fisher, Tosoh and other suppliers.

Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

Technology Review

- Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for the microbiology market.

- Global listings of companies developing or marketing microbiology products by individual test.

Competitive Assessments

- Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

- The companies analyzed in the report include Abbott Laboratories, Agilent Technologies, Beckman Coulter/Danaher, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Fujirebio, Grifols, Instrumentation Laboratory/Werfen, Kyowa Medex, Ortho-Clinical Diagnostics, PerkinElmer, Quest Diagnostics, Roche, Siemens Healthineers, Sysmex, Thermo Fisher, Tosoh, and Wako.

Opportunities and Strategic Recommendations

- Emerging opportunities for new analyzers, reagents kits, IT and other products with significant market appeal during the next five years.

- Design criteria for decentralized testing products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Fill The Form For Sample Request

There is no Reviews available